Sofia Rivera, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses the Phase III HypoG-01 trial (NCT03127995), which assessed the non-inferiority of hypofractionated (HF) radiotherapy (RT) versus normofractionated (NF) radiotherapy for loco-regional early breast cancer. The study evaluated arm lymphedema risk as the primary endpoint, demonstrating non-inferiority of HF radiotherapy. Secondary endpoints, including locoregional relapse-free survival, distant disease-free survival, and overall survival, also favored HF treatment. These findings suggest HF radiotherapy as a safe, effective, and practice-changing option for early breast cancer patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
